Due to the pivotal role of p53 as a tumor suppressor, p53 activation through HDAC8 inhibition is a potential therapeutic strategy and has been shown to be effective in ovarian cancer, hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML) [28,66,67,68]. Here, HDAC8 is linked to neoplasm.